Structure Therapeutics' (GPCR) subsidiary Gasherbrum Bio signed a patent license agreement with Genentech, granting Genentech ...

Adhesion GPCRs belong to the large family of G protein-coupled receptors (GPCRs). There are about 700 variants in humans, which are responsible for sensory impressions, hormonal cycles, controlling ...

Adhesion G protein-coupled receptors have a large extracellular region (shown in green and orange) that extends into space outside the cell. Almost 35% of drugs approved by the Food and Drug ...

Adhesion GPCRs are a group of cell-surface sensors associated with many body functions and diseases. However, they are not yet sufficiently understood to be exploited for therapies. Scientists have ...

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has issued an update. On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure ...

Scientists reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands. Through an international collaboration, scientists at St. Jude ...

Structure Therapeutics GPCR, a clinical-stage company, is expected to report second-quarter 2024 results soon. Structure Therapeutics’ lead product candidate is GSBR-1290, a highly selective oral ...

Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...